115 related articles for article (PubMed ID: 38771994)
21. Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial.
Raman R; Quiroz YT; Langford O; Choi J; Ritchie M; Baumgartner M; Rentz D; Aggarwal NT; Aisen P; Sperling R; Grill JD
JAMA Netw Open; 2021 Jul; 4(7):e2114364. PubMed ID: 34228129
[TBL] [Abstract][Full Text] [Related]
22. Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups.
Wang J; Qiao Y; Shih YC; Jarrett-Jamison J; Spivey CA; Wan JY; White-Means SI; Dagogo-Jack S; Cushman WC; Chisholm-Burns M
J Manag Care Spec Pharm; 2015 Nov; 21(11):993-1003. PubMed ID: 26521111
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies.
Wei W; Kurita T; Hess KR; Sanft T; Szekely B; Hatzis C; Pusztai L
JAMA Oncol; 2018 Apr; 4(4):e175092. PubMed ID: 29372234
[TBL] [Abstract][Full Text] [Related]
24. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy.
Angeles A; Hung W; Cheung WY
Med Oncol; 2018 Jun; 35(8):114. PubMed ID: 29936654
[TBL] [Abstract][Full Text] [Related]
25. Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?
Al-Baimani K; Jonker H; Zhang T; Goss GD; Laurie SA; Nicholas G; Wheatley-Price P
Curr Oncol; 2018 Aug; 25(4):e291-e297. PubMed ID: 30111974
[TBL] [Abstract][Full Text] [Related]
26. Eligibility criteria in clinical trials in breast cancer: a cohort study.
Szlezinger K; Pogoda K; Jagiełło-Gruszfeld A; Kłosowska D; Górski A; Borysowski J
BMC Med; 2023 Jul; 21(1):240. PubMed ID: 37400830
[TBL] [Abstract][Full Text] [Related]
27. The impact of socioeconomic status and race on trial participation for older women with breast cancer.
Gross CP; Filardo G; Mayne ST; Krumholz HM
Cancer; 2005 Feb; 103(3):483-91. PubMed ID: 15597407
[TBL] [Abstract][Full Text] [Related]
28. Who is eligible for randomized trials? A comparison between the exclusion criteria defined by the ISCHEMIA trial and 3102 real-world patients with stable coronary artery disease undergoing stent implantation in a single cardiology center.
Wasilewski J; Poloński L; Lekston A; Osadnik T; Reguła R; Bujak K; Kurek A
Trials; 2015 Sep; 16():411. PubMed ID: 26373291
[TBL] [Abstract][Full Text] [Related]
29. Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center.
Nachtkamp K; Stark J; Kündgen A; Schroeder T; Strupp C; Strapatsas J; Schuler E; Kaivers J; Giagounidis A; Rautenberg C; Aul C; Runde V; Haas R; Kobbe G; Gattermann N; Germing U
Leuk Res; 2021 Sep; 108():106611. PubMed ID: 33990002
[TBL] [Abstract][Full Text] [Related]
30. Metastatic gastroesophageal cancer in older patients - is this patient cohort represented in clinical trials?
Hennessy MA; Hamid M; Keegan NM; Corrigan L; Goggin C; Oo NM; Carrigan M; Mockler D; O'Donovan A; Horgan AM
BMC Cancer; 2022 Jan; 22(1):3. PubMed ID: 34980003
[TBL] [Abstract][Full Text] [Related]
31. Racial and Ethnic Disparities in Clinical Trial Enrollment Among Women With Gynecologic Cancer.
Khadraoui W; Meade CE; Backes FJ; Felix AS
JAMA Netw Open; 2023 Dec; 6(12):e2346494. PubMed ID: 38060227
[TBL] [Abstract][Full Text] [Related]
32. Socioeconomic status and inequities in treatment initiation and survival among patients with cancer, 2011-2022.
Guadamuz JS; Wang X; Ryals CA; Miksad RA; Snider J; Walters J; Calip GS
JNCI Cancer Spectr; 2023 Aug; 7(5):. PubMed ID: 37707536
[TBL] [Abstract][Full Text] [Related]
33. Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials.
Riner AN; Girma S; Vudatha V; Mukhopadhyay N; Skoro N; Gal TS; Freudenberger DC; Herremans KM; George TJ; Trevino JG
J Clin Oncol; 2022 Jul; 40(20):2193-2202. PubMed ID: 35316089
[TBL] [Abstract][Full Text] [Related]
34. Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the 'real world'.
Jeremias A; Ruisi CP; Kirtane AJ; Lee T; Sylvia B; Pinto DS; Ho KK; Cutlip DE; Carrozza JP; Cohen DJ
Coron Artery Dis; 2008 Mar; 19(2):111-5. PubMed ID: 18300748
[TBL] [Abstract][Full Text] [Related]
35. Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study.
Berden FA; de Knegt RJ; Blokzijl H; Kuiken SD; van Erpecum KJ; Willemse SB; den Hollander J; van Vonderen MG; Friederich P; van Hoek B; van Nieuwkerk CM; Drenth JP; Kievit W
PLoS One; 2016; 11(9):e0161821. PubMed ID: 27598789
[TBL] [Abstract][Full Text] [Related]
36. The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials.
Donia M; Kimper-Karl ML; Høyer KL; Bastholt L; Schmidt H; Svane IM
Eur J Cancer; 2017 Mar; 74():89-95. PubMed ID: 28335891
[TBL] [Abstract][Full Text] [Related]
37. Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland.
Baillie K; Mueller T; Pan J; Laskey J; Bennie M; Crearie C; Kavanagh K; Alvarez-Madrazo S; Morrison D; Clarke J; Keel A; Cameron D; Wu O; Kurdi A; Jones RJ
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):653-663. PubMed ID: 32316077
[TBL] [Abstract][Full Text] [Related]
38. Racial and ethnic disparities in meeting MTM eligibility criteria among patients with asthma.
Lu D; Qiao Y; Johnson KC; Wang J
J Asthma; 2017 Jun; 54(5):504-513. PubMed ID: 27676212
[TBL] [Abstract][Full Text] [Related]
39. Evaluating eligibility criteria of oncology trials using real-world data and AI.
Liu R; Rizzo S; Whipple S; Pal N; Pineda AL; Lu M; Arnieri B; Lu Y; Capra W; Copping R; Zou J
Nature; 2021 Apr; 592(7855):629-633. PubMed ID: 33828294
[TBL] [Abstract][Full Text] [Related]
40. Ineligible, Unaware, or Uninterested? Associations Between Underrepresented Patient Populations and Retention in the Pathway to Cancer Clinical Trial Enrollment.
Caston NE; Lalor F; Wall J; Sussell J; Patel S; Williams CP; Azuero A; Arend R; Liang MI; Rocque GB
JCO Oncol Pract; 2022 Nov; 18(11):e1854-e1865. PubMed ID: 36178922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
